Reversal of drug resistance in ovarian cancer: where do we go from here?
- PMID: 18509172
- DOI: 10.1200/JCO.2008.16.2123
Reversal of drug resistance in ovarian cancer: where do we go from here?
Comment on
-
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.J Clin Oncol. 2008 Jun 1;26(16):2674-82. doi: 10.1200/JCO.2007.14.9807. J Clin Oncol. 2008. PMID: 18509179 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
